Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 1.40M | 200.00K | 1.80M | 2.19M | 7.13M | 12.81M |
Gross Profit | -1.39M | -2.08M | 609.00K | -107.99M | 4.44M | -60.69M |
EBITDA | -157.62M | 1.70B | -206.69M | -125.82M | -75.37M | -66.42M |
Net Income | -163.69M | 1.69B | -241.36M | -145.23M | -81.77M | -75.64M |
Balance Sheet | ||||||
Total Assets | 212.12M | 180.77M | 307.89M | 290.88M | 150.45M | 143.74M |
Cash, Cash Equivalents and Short-Term Investments | 186.57M | 152.60M | 277.92M | 273.87M | 131.30M | 128.66M |
Total Debt | 7.51M | 8.05M | 210.14M | 207.10M | 70.47M | 37.45M |
Total Liabilities | 143.56M | 47.18M | 264.39M | 232.82M | 98.07M | 68.27M |
Stockholders Equity | 68.56M | 133.58M | 43.50M | 58.06M | 52.38M | 75.47M |
Cash Flow | ||||||
Free Cash Flow | -140.13M | -197.01M | -197.90M | -115.99M | -81.19M | -49.33M |
Operating Cash Flow | -139.85M | -194.41M | -193.31M | -115.30M | -80.32M | -47.97M |
Investing Cash Flow | -284.00K | -2.60M | -4.59M | -686.00K | -809.00K | -1.36M |
Financing Cash Flow | 102.55M | 71.68M | 201.96M | 258.55M | 83.77M | 166.46M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
58 Neutral | $375.39M | 0.20 | -113.71% | ― | ― | ― | |
58 Neutral | $329.83M | 3.50 | 108.21% | ― | 18.01% | 306.76% | |
56 Neutral | $6.56B | -0.98 | 0.45% | 6.27% | 14.92% | 10.98% | |
55 Neutral | $449.48M | ― | -66.85% | ― | -95.24% | -493.05% | |
52 Neutral | $288.42M | 13.61 | 9.81% | ― | 2990.57% | ― | |
42 Neutral | $232.81M | ― | -257.38% | ― | ― | 63.92% | |
33 Underperform | $327.17M | ― | -55.18% | ― | ― | 60.29% |
Inhibrx Biosciences, Inc. held its 2025 Annual Meeting of Stockholders on May 28, 2025, in a virtual format. During the meeting, a quorum of approximately 79% of eligible shares was present. Key outcomes included the election of Jon Faiz Kayyem, Ph.D., and Kristiina Vuori, M.D., Ph.D., as Class I Directors to serve until the 2028 Annual Meeting, and the ratification of BDO USA, P.C. as the independent registered public accounting firm for the year ending December 31, 2025.